As of January 2020 the FDA issued the following safety communication:
The FDA has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.
When FDA approved lorcaserin in 2012, FDA required the drug manufacturer to conduct a clinical trial to evaluate the risk of cardiovascular problems. A range of cancer types was reported, with several different types of cancers occurring more frequently in the lorcaserin group, including pancreatic, colorectal, and lung.
If you or a loved one has contracted one of the above types of cancers and was taking Belviq or Belviq XR, please contact us immediately for a free evaluation of your claim.
336 S. MAIN ST.
Bel Air, MD 21014